(MENAFN- PR Newswire)
NEW ORLEANS, Nov. 19, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Dicerna Pharmaceuticals, Inc. (NasdaqGS: DRNA) to Novo Nordisk A/S (NYSE: NVO ). Under the terms of the proposed transaction, shareholders of Dicerna will receive $38.25 in cash for each share of Dicerna that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected] ) toll free at any time at 855-768-1857, or visit to learn more.
Please note that the merger is structured as a tender offer, such that time may be of the essence.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit .
Kahn Swick & Foti, LLC1100 Poydras St., Suite 3200New Orleans, LA 70163
SOURCE Kahn Swick & Foti, LLC
MENAFN20112021003732001241ID1103208483
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.